Compare Bristol-Myers Squibb Co (BMY) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Grab Holdings Ltd. — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while Grab Holdings Ltd. trades at $3.63 (market cap $15.26B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.5× Grab Holdings Ltd.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| BMY | GRAB | |
|---|---|---|
Market Cap | $129.94B | $15.26B |
Sector | Health | Technology |
52-Week High | $65.89 | $6.45 |
52-Week Low | $42.60 | $3.27 |
Enterprise Value | $163.92B | $10.99B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
GRAB trades at $3.625, down 1.23% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and a significant turnaround to profitability. The company reported Q2 2026 EPS of $0.06 versus $0.05 expected, with revenue growth accelerating to $3.37 billion in 2025. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions near-term.
GRAB presents a compelling growth story with improving profitability and strong analyst support (91.67% buy ratings). The company's raised 2026 guidance and expanding super app ecosystem signal continued momentum. Key risks include volatile cash flow patterns, competitive pressures in Southeast Asia, and recent insider selling activity that warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
